Connect with us

Health

New pancreatic cancer treatment ‘wakes up’ immune cells, researchers say

Published

on

New pancreatic cancer treatment ‘wakes up’ immune cells, researchers say

NEWYou can now listen to Fox News articles!

Scientists have created a new antibody treatment that helps the immune system recognize and attack pancreatic cancer.

Pancreatic cancer cells use a sugary “disguise” to trick the immune system into ignoring them.

Most current cancer immunotherapies target proteins or genes, but this new therapy focuses on the sugars on the cell surface, blocking them so that immune cells can find and attack the cancer, according to researchers from Northwestern University in Chicago.

CANCER VACCINE SHOWS PROMISE IN PREVENTING RECURRENCE OF PANCREATIC, COLORECTAL TUMORS

Advertisement

“Pancreatic cancer is notoriously good at hiding from the immune system, but we were struck that a single sugar, called sialic acid, can so powerfully fool immune cells,” senior author Mohamed Abdel-Mohsen, associate professor of medicine in the division of infectious diseases at Northwestern University Feinberg School of Medicine, told Fox News Digital. 

“When tumors sugar-coat themselves with this molecule, it flips an immune ‘off switch’ on certain immune cells, essentially signaling, ‘I’m a normal, healthy cell; don’t attack.’”

Study authors Mohamed Abdel-Mohsen (top) and Pratima Saini (foreground) are pictured in Abdel-Mohsen’s lab. (Northwestern University)

In mice studies, the therapy was shown to be successful in blocking this sugar signal, “waking up” immune cells and slowing cancer’s growth.

In two mouse models, tumors treated with the antibody grew significantly slower than groups that did not receive the treatment, the study showed.

Advertisement

CANCER SURVIVAL APPEARS TO DOUBLE WITH COMMON VACCINE, RESEARCHERS SAY

These findings could pave the way toward testing in human groups, and could potentially be combined with chemotherapy and existing immunotherapies, according to the researchers.

The findings were published in the journal Cancer Research on Nov. 3.

Study senior author Mohamed Abdel-Mohsen is shown in his lab. “This is early-stage, preclinical research, not a treatment today, but it opens a new immune target in pancreatic cancer,” he said. (Northwestern University)

“This is early-stage, preclinical research, not a treatment today, but it opens a new immune target in pancreatic cancer,” said Abdel-Mohson.

Advertisement

Heloisa P. Soares, M.D., Ph.D., medical director of theranostics at Huntsman Cancer Institute and associate professor of internal medicine at the University of Utah, said this research is “encouraging” because it points to a new way of helping the immune system recognize and fight pancreatic cancer.

“Pancreatic cancer is notoriously good at hiding from the immune system.”

“It was surprising to learn that a protein usually responsible for helping cells stick together is also being used by pancreatic cancer as a hidden ‘do-not-attack’ signal,” Soares, who was not involved in the study, told Fox News Digital.

“The striking part was that when this signal was blocked, the immune cells woke back up and started attacking the tumor much more effectively — which suggests a promising new direction for treatment.”

CANCER TREATMENT COULD BE LESS EFFECTIVE IF PATIENTS CONSUME POPULAR SWEETENER

Advertisement

Pancreatic cancer is one of the most lethal forms of the disease. It’s usually detected at an advanced stage, leaving patients with limited treatment choices and a five-year survival rate of only about 13%, the researchers noted.

Unlike many other cancers, it often doesn’t respond to immunotherapy.

Pancreatic cancer is usually detected at an advanced stage, leaving patients with limited treatment choices and a five-year survival rate of only about 13%. (iStock)

“Pancreatic cancer is often diagnosed late, in part because it remains asymptomatic and is deep in the body,” Dr. Marc Siegel, Fox News senior medical analyst, told Fox News Digital.

“It is also difficult to treat because it doesn’t have many good immune targets and doesn’t mutate that much.”

Advertisement

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

The study did have some limitations, the researchers acknowledged — primarily that the tests have only been conducted on animals thus far and there is not yet any human data.

“Animal models cannot capture all the complexity of human pancreatic cancer,” the lead researcher noted. “Tumors also use multiple escape routes, so this strategy will likely be part of a combination approach.”

After human trials, the researchers estimate that it could take about five years before the therapy would be available to patients. (Northwestern University)

The long-term safety and dosing parameters of the therapy are also unknown.

Advertisement

“We need clinical trials to see how effective this is in humans and whether it has a role in cancer treatments for this difficult and deadly cancer — but it is quite promising,” Siegel added.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

The research team is now working with clinicians at Northwestern’s Robert H. Lurie Comprehensive Cancer Center on next steps toward potential human studies, likely in combination with current chemotherapy and immunotherapies, according to Abdel-Mohsen.

“It’s a promising step forward, but not something that will change care overnight.”

“If future studies support it, this approach could be added to the toolbox against pancreatic cancer, likely alongside existing chemo-immunotherapy, not replacing what’s working today,” he told Fox News Digital.

Advertisement

After human trials, the researchers estimate that it could take about five years before the therapy would be available to patients.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Soares added, “It’s a promising step forward, but not something that will change care overnight. Continued funding and participation in clinical trials are essential to keep this progress moving.”

CLICK HERE FOR MORE HEALTH STORIES

The study was supported in part by the National Institutes of Health.

Advertisement

Health

Sleeping 11 minutes longer each night shows surprising health benefit, study finds

Published

on

Sleeping 11 minutes longer each night shows surprising health benefit, study finds

NEWYou can now listen to Fox News articles!

The secret to a healthier heart may not be a major lifestyle overhaul, but rather a series of small, sustainable daily habits.

New research published in the European Journal of Preventive Cardiology found that combining modest shifts in daily habits is associated with a significantly reduced risk of major cardiovascular events, including heart attacks, stroke and heart failure.

The study, which followed more than 53,000 adults over an eight-year period, highlighted how even the smallest increase in rest can yield clinically meaningful benefits.

SPECIFIC AMOUNT OF NIGHTLY SLEEP MAY LOWER DIABETES RISK, RESEARCHERS FIND

Advertisement

Researchers found that sleeping for just 11 minutes more per night was a key component of a lifestyle shift associated with a 10% lower risk of major cardiovascular events.

Small daily habits like getting just 11 extra minutes of sleep each night can significantly reduce the risk of heart problems. (iStock)

This modest increase in sleep was most effective when paired with an additional 4.5 minutes of moderate-to-vigorous physical activity and eating an extra quarter-cup of vegetables every day.

“We show that combining small changes in a few areas of our lives can have a surprisingly large positive impact on our cardiovascular health,” said lead author Nicholas Koemel, a research fellow at the University of Sydney.

CLICK HERE FOR MORE HEALTH STORIES

Advertisement

While every extra minute counts, the study identified an ideal range for maximum heart protection that could slash the risk of heart disease by 57% compared to those with the least healthy habits.

The primary pillar of that profile was achieving eight to nine hours of sleep per night, the study noted.

Getting eight to nine hours of sleep each night, along with consistent healthy habits, can reduce the risk of heart disease by up to 57%. (iStock)

This optimal routine also included completing 42 minutes or more of moderate physical activity per day and maintaining a diet high in fish, whole grains, and dairy while remaining low in processed meats and sugary drinks.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Advertisement

“Making even modest shifts in our daily routines is likely to have cardiovascular benefits as well as create opportunities for further changes in the long run,” Koemel added. “I would encourage people not to overlook the importance of making a small change or two to your daily routine, no matter how small they may seem.”

Researchers utilized wearable devices to track the sleep and movement of participants, providing more accurate data than previous self-reported studies.

This ideal routine also involves a diet rich in fish, whole grains, and dairy while limiting processed meats and sugary drinks. (iStock)

Several limitations were noted for the research.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Advertisement

The study was observational, meaning it showed a strong link between these small habits and heart health but could not prove that one directly caused the other.

The findings were also based on participants reporting their own dietary habits, which may not always be perfectly accurate.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

The researchers emphasized that studying these behaviors together is more meaningful than looking at them in isolation because sleep, diet and movement are constantly influencing one another in a daily cycle.

Advertisement
Continue Reading

Health

Cases of ‘white plague’ rising in US as doctors warn of ‘rebound effect’

Published

on

Cases of ‘white plague’ rising in US as doctors warn of ‘rebound effect’

NEWYou can now listen to Fox News articles!

A potentially deadly disease known as “the white plague” has been rising in the U.S. since the pandemic, health officials have warned.

Tuberculosis (TB) gets its nickname from the pale appearance of those affected with the disease.

After a dip in 2020 with the onset of COVID – likely due to underdiagnosis and reduced screenings, according to health experts – cases of TB have increased every year since.

MENINGITIS CASES RISE IN MAJOR MIDWESTERN CITY, PROMPTING PUBLIC HEALTH ALERT

Advertisement

More than 10,600 cases were confirmed in 2024, which is around three people for every 100,000, per the latest available data from the Centers for Disease Control and Prevention.

This marks the third consecutive annual increase, and the total 2024 case count is the highest annual number since 2013.

After a dip in 2020 with the onset of COVID, cases of tuberculosis have increased every year since. (iStock)

Despite the recent increase, TB rates in the U.S. remain relatively low compared to many parts of the world, as the global average is about 131 cases per 100,000, per the World Health Organization. That’s approximately 40 times higher globally compared to the U.S.

TB is a curable bacterial infection that targets the lungs, but can also infect other organs, according to Johns Hopkins. It is spread through airborne particles released when an infected person coughs, speaks or sneezes.

Advertisement

URGENT WARNING ISSUED BY CDC AS CHIKUNGUNYA VIRUS OUTBREAK HITS VACATION DESTINATION

Renuga Vivekanandan, M.D., professor at Creighton University School of Medicine and VP and CMO of CHI Health Physician Enterprise Midwest, said the rise in tuberculosis cases in the U.S. is concerning, but noted that it was foreseeable.

“The COVID-19 pandemic effectively disrupted TB surveillance and treatment programs across the country,” the doctor, who is board-certified in internal medicine and infectious diseases, told Fox News Digital. 

TB is a curable bacterial infection that targets the lungs, but can also infect other organs, according to Johns Hopkins. (Getty)

“What we’re seeing now is largely a rebound effect – latent TB infections that went undetected or untreated during the pandemic are now activating.”

Advertisement

Another factor is a return to international travel and increased migration from countries where TB is more prevalent, according to Vivekanandan.

The uptick has also strained healthcare systems. “Local and state public health TB programs became understaffed during the pandemic, and that capacity hasn’t fully recovered,” the doctor said.

Symptoms of disease

While around 25% of people have likely been infected with the TB bacteria, about 5% to 10% will go on to develop active disease, according to health agencies.

MEASLES OUTBREAK POSES RISK OF ‘IRREVERSIBLE’ BRAIN DAMAGE, HEALTH OFFICIALS WARN

A person with a latent infection has been infected with the tuberculosis bacteria, but the bacteria are inactive in the body. While latent-stage TB is not contagious, it can develop into active disease in 5% to 10% of people. 

Advertisement

Only people with active TB disease in the lungs or throat can spread the infection.

While around 25% of people have likely been infected with the TB bacteria, about 5% to 10% will go on to develop active disease. (iStock)

Those who get sick with TB may experience mild symptoms, including coughing, chest pain, fatigue, weight loss, weakness, fever and night sweats, per the CDC. In some cases, however, the disease can also affect the kidneys, spine, skin and brain.

CLICK HERE FOR MORE HEALTH STORIES

“TB can affect any organ of the body, but it causes disease in the lung in over 80% of cases,” Masae Kawamura, M.D., a former TB control director in San Francisco and a tuberculosis clinician, previously told Fox News Digital. “This is dangerous because it causes cough, the mechanism of airborne spread.”

Advertisement

“TB can affect any organ of the body, but it causes disease in the lung in over 80% of cases.”

In more severe cases, patients may cough up blood, noted Kawamura, who serves on the board of directors of Vital Strategies, a global public health organization.

“Often, there are minimal symptoms for a long time, and people mistake their occasional cough with allergies, smoking or a cold they can’t shake off,” she added.

Risk factors, treatment and prevention

“The good news is that TB is both preventable and treatable,” Vivekanandan said.

“People who are at higher risk – including those born in or traveling frequently to high TB-burden countries, individuals living in crowded conditions, or those who are immunocompromised – should speak with their doctor about TB testing.”

Advertisement

“People who are at higher risk – including those born in or traveling frequently to high TB-burden countries, individuals living in crowded conditions, or those who are immunocompromised – should speak with their doctor about TB testing,” one doctor noted. (iStock)

Other high-risk groups include people who have diabetes, are malnourished, use tobacco and/or drink excess amounts of alcohol. Babies and children are also more vulnerable to the disease.

Doctors typically use a skin or blood test to detect TB infection, followed by imaging or sputum (mucus) testing to confirm active disease, per the CDC.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

The disease is treated with antibiotics that are taken every day for four to six months, the CDC states. Some of the most common include isoniazid, rifampicin, pyrazinamide and ethambutol.

Advertisement

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Failure to take the complete course of medications can cause the bacteria to become drug-resistant, which means it does not respond to standard antibiotics. Drug-resistant TB is more difficult and costly to treat and requires longer, more complex medication regimens, according to experts.

If TB goes untreated, it is fatal in about half of its victims.

“Latent TB, which causes no symptoms and is not contagious, can be treated and cured before it ever progresses to active TB, which is infectious,” the doctor pointed out. (iStock)

“Latent TB, which causes no symptoms and is not contagious, can be treated and cured before it ever progresses to active TB, which is infectious,” Vivekanandan said.

Advertisement

“Identifying and treating latent infection is one of the most powerful tools we have for protecting both individual patients and the broader community.”

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ 

The U.S. Preventive Services Task Force recommends screening only for populations at increased risk rather than for the general population.

Continue Reading

Health

Hormone therapy boosts weight loss drug results by 35% in women, study finds

Published

on

Hormone therapy boosts weight loss drug results by 35% in women, study finds

NEWYou can now listen to Fox News articles!

For women struggling with weight gain after menopause, a new study suggests that adding hormone therapy to a popular obesity drug may lead to greater weight loss.

Postmenopausal women lost about 35% more weight when using menopausal hormone therapy alongside tirzepatide — a GLP-1-based, Food and Drug Administration-approved drug for the overweight and obese — compared to those taking the drug alone, according to a Mayo Clinic study.

The findings, published in February in The Lancet Obstetrics, Gynaecology, & Women’s Health, highlight a possible new strategy for addressing weight gain after menopause, when hormonal shifts can increase the risk of obesity, cardiovascular disease and Type 2 diabetes.

STOPPING OZEMPIC? NEW STUDY REVEALS SURPRISING WEIGHT REGAIN RESULTS AFTER GLP-1S

Advertisement

“This study provides important insights for developing more effective and personalized strategies for managing cardiometabolic risk in postmenopausal women,” Dr. Regina Castaneda, the study’s first author, said in a statement. 

A new study found that postmenopausal women lost more weight when combining hormone therapy with a GLP-1-based drug. (iStock)

Researchers analyzed 120 postmenopausal women who were overweight or obese who took tirzepatide for at least 12 months, including 40 who also used hormone therapy and 80 who did not.

Hormone therapy is commonly used to treat menopause symptoms like hot flashes and night sweats, while tirzepatide helps regulate appetite and blood sugar.

WEIGHT LOSS MEDICATIONS COULD IMPACT SEXUAL HEALTH IN UNEXPECTED WAYS

Advertisement

Women in the hormone therapy group lost an average of 19.2% of their body weight, compared to 14.0% in the non-hormone group — about 35% greater relative weight loss — with more women reaching significant weight-loss thresholds, according to the study.

Despite the results, researchers emphasized that the study was observational and cannot prove cause and effect.

Hormonal changes after menopause can increase weight gain and health risks. (iStock)

“Because this was not a randomized trial, we cannot say hormone therapy caused additional weight loss,” said Dr. Maria Daniela Hurtado Andrade, an endocrinologist at Mayo Clinic and senior author of the study.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Advertisement

Outside experts agree that the findings must be interpreted cautiously.

“As with all observational studies, we need to interpret this study with a grain of salt,” Dr. Gillian Goddard, a board-certified endocrinologist, told Fox News Digital. 

Goddard, who is also an adjunct assistant professor of medicine at the NYU Grossman School of Medicine, noted that the findings show a link but do not prove that hormone therapy, which usually includes estrogen, directly caused the additional weight loss.

CLICK HERE FOR MORE HEALTH STORIES

“There may be important differences between the two groups,” she added. “For one thing, the group taking estrogen may be healthier than the groups that didn’t take estrogen. … Healthier people are more likely to eat a healthy diet and exercise in addition to taking tirzepatide. That could lead to more weight loss.” 

Advertisement

Tirzepatide, a GLP-1-based drug, may be more effective for weight loss when paired with hormone therapy, according to researchers. (iStock)

Symptom relief from the therapy may have also improved sleep and well-being, making it easier for the group to maintain diet and exercise routines, Hurtado Andrade noted.

Researchers also pointed to a possible biological explanation. Preclinical data suggest estrogen may enhance the appetite-suppressing effects of GLP-1-based medications like tirzepatide, according to the study.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Goddard said that theory is plausible but unproven.

Advertisement

Hormone therapy may ease menopause symptoms and help women stay on track with diet and exercise. (iStock)

“The other possibility is that estrogen interacts with tirzepatide in some way that makes it more potent,” she said. “We will need randomized studies to get a better handle on that.”

As for safety, experts say using the two together appears safe for most women. However, hormone therapy is not recommended for all patients, especially those with a history of certain cancers, blood clots or other underlying health risks, according to the Mayo Clinic.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Researchers say future randomized trials will aim to confirm the findings and explore whether the combination also improves broader cardiometabolic health outcomes, according to the study.

Advertisement

Experts say more research is needed to confirm whether hormone therapy directly boosts weight loss results with GLP-1 drugs. (iStock)

“If confirmed, this work could speed the development and adoption of new, evidence-based strategies to reduce this risk for millions of postmenopausal women navigating this life stage,” Hurtado Andrade said.

Fox News Digital has reached out to the study authors for comment.

Continue Reading

Trending